article thumbnail

Renova Therapeutics Raises $7.52M

socalTECH

Bradbury has joined the company''s board. Bradbury is a member of life sciences consulting and investment firm BioBrit LLC; he also served as President and CEO of Amylin Pharmaceuticals. The company said the funding primarily came from high net worth individuals. As part of the funding, Daniel M. READ MORE>>.

Bradbury 138
article thumbnail

Alume Biosciences Gets $5.5M

socalTECH

According to Alume, the funding came from angel investors, including co-founder Chrysa Mineo (formerly of Receptos and Neurocrine Biosciences) and Dan Bradbury (co-founder and Executive Chairman of Equillium, Inc. La Jolla-based biotechnology startup Alume Biosciences announced that it has raised $5.5M and former CEO of Amylin).

Bradbury 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biolinq Raises $10M

socalTECH

As part of the funding Dan Bradbury, the former CEO of Amylin Pharmaceuticals, has joined as executive chairman, and M Ventures' Edwards Kliphuis, along with Hikma Ventures' Lana Ghanem have both joined the company's board. Biolinq is led by CEO Jared Tangney.

Bradbury 113
article thumbnail

Liquid Grids Gets Series A For Healthcare Marketing

socalTECH

Bradbury, former CEO of Amylin Pharmacueticals, as a new Chairman of its board, and also added Sherman Atkinson as a Director of the company with the funding. The company said it has added Daniel M. READ MORE>>. liquidgrids liquid grids venture capital healthcare marketing advertising'

Bradbury 100
article thumbnail

Teaching a Kid to Swim One Way or Another

Eric Greenspan

Tom Bradbury. Moms shrieked. Five or so minutes later, the kid would swim to Tom. Then again and again and that was it. He was swimming! Here’s a great piece on the infamous [Swim to.] For the next few months, if my son acted up, a simple “I’m calling Tom” would get him immediately in line.

Bradbury 103
article thumbnail

After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

Xconomy

Headed by former Amylin CEO Dan Bradbury, Equillium (NASDAQ: EQ ) has licensed the drug, itolizumab, which it calls EQ001, from Indian pharma giant Biocon Limited for development in the United States and Canada. Equillium was formed to advance.